Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS-FGFR4RX · 1 trial · 1 indication
As measured by: * Resting Metabolic rate (kcal/min) * Resting metabolic rate adjusted for changes in body composition (kcal/min) * Resting fat oxidation (grams/24 hr)
| Arm | Type | Description |
|---|---|---|
| ISIS-FGFR4RX | EXPERIMENTAL | ISIS-FGFR4RX administered subcutaneously |
| Placebo | PLACEBO_COMPARATOR | Placebo administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| ISIS-FGFR4RX | DRUG | ISIS-FGFR4RX administered subcutaneously |
| Placebo | DRUG | Placebo administered subcutaneously |
Inclusion Criteria: 1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements 2. Male or female patients between the age of 18-65 years, inclusive * Females: Must be post-menopausal (defined as 1...
Top 20 of 32 competitors
ISIS-FGFR4RX is an investigational small molecule being developed for the treatment of obesity. It is a Phase 2 drug candidate that has been studied in obese patients to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
ISIS-FGFR4RX is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical research on this drug candidate for obesity.
ISIS-FGFR4RX is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its safety and other characteristics in obese patients.
ISIS-FGFR4RX has been studied in one completed Phase 2 clinical trial with the identifier NCT02476019. This trial was a randomized, double-blind, placebo-controlled study conducted in the United States, enrolling 13 obese patients aged 18 years and older.
ISIS-FGFR4RX is the drug name used in clinical trials. No alternative names have been reported for this investigational candidate. It is being studied under this name by Ionis Pharmaceuticals for the treatment of obesity.